• Publications
  • Influence
Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.
Dramatic reductions in IPD after PCV7 introduction in the United States remain evident 7 years later, and IPD rates caused by serotype 19A and other non-PCV7 types have increased but remain low relative to decreases in PCV 7-type IPD. Expand
Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 — COVID-NET, 14 States, March 1–30, 2020
  • S. Garg, L. Kim, +35 authors A. Fry
  • Medicine
  • MMWR. Morbidity and mortality weekly report
  • 17 April 2020
It is suggested that older adults have elevated rates of COVID-19-associated hospitalization and the majority of persons hospitalized with CO VID-19 have underlying medical conditions, which underscore the importance of preventive measures to protect older adults and persons with underlyingmedical conditions, as well as the general public. Expand
Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005.
Among infants from birth through 6 days, the incidence of group B streptococcal disease was lower in 2003-2005 relative to 1999-2001, and this reduction coincided with the release of revised disease prevention guidelines in 2002. Expand
Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004.
The incidence of pneumococcal disease caused by nonvaccine serotypes is increasing and Ongoing surveillance is needed to monitor the magnitude of disease cause by non vaccines, to ensure that future vaccines target the appropriate serotypes. Expand
Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.
PCV13 reduced IPD across all age groups when used routinely in children in the USA, providing reassurance that, similar to PCV7, PCVs with additional serotypes can also prevent transmission to unvaccinated populations. Expand
Bacterial meningitis in the United States, 1998-2007.
The rates of bacterial meningitis have decreased since 1998, but the disease still often results in death, and the burden of bacterialMeningitis is now borne more by older adults. Expand
Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990-2007.
Invasive GBS disease in nonpregnant adults represents a substantial and increasing burden, particularly among older persons, black persons, and adults with diabetes, and prevention strategies are needed. Expand
Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine.
The findings indicate that use of conjugate vaccine in children has substantially benefited older adults, and persons with certain comorbid conditions may benefit less than healthier persons from the indirect effects of the new vaccine. Expand
Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study
The seven-valent pneumococcal conjugate vaccine prevents invasive disease in both healthy and chronically ill children and is effective when used with various non-standard schedules. Expand
Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae.
The rate of antibiotic-resistant invasive pneumococcal infections decreased in young children and older persons after the introduction of the conjugate vaccine, and there was an increase in infections caused by serotypes not included in the vaccine. Expand